Company: OSRH
Filing Date: 2025-01-31
Form Type: 424B3
Source: 0001213900-25-008874
Chunk: 395

Company: OSR Holdings, Inc.
Filing Date: 2025-01-31
Form: 424B3
Chunk 395
---
 diversified portfolio to address unmet medical needs with resilience and efficiency. 239

Our corporate organization and ownership of subsidiaries is illustrated by the following chart*: ____________ *Excludes a 33.3% interest in Taction Co. Ltd, a dormant Korea company with no operations. Portfolio Overview OSR Holdings’ subsidiaries (other than RMC) have diverse scientific and technological developments, and are engaged in distinct areas of therapeutics research and development, including oral T -cellimmunotherapies and recombinant biologics. This approach not only provides OSR Holdings with a broader scope of potential therapeutic solutions but also reduces the risks associated with a singular -assetapproach. Figure 2 below summarizes our three subsidiaries, two of which have their own drug development pipelines.

| Portfolio Company |     | Science, Technology and Platform                                                                                                                                                                                 |
|                   |     | T-cell immunotherapies based on a live attenuated, safe, orally, available bacterial vaccine strain, genetically modified to develop and elicit patients’ cytotoxic T-cells against specific pre-defined targets |
|                   |     | Platform integrating different protein domain sequences linking into a Design augmented recombinant biologic with enhanced biological functionality                                                              |
|                   |     | Neurovascular surgical devices                                                                                                                                                                                   |

Figure 2. OSR Holdings portfolio company snapshot. Intellectual Property Overview We own or have in -licensednumerous patents and intellectual property underlying patent applications and possess substantial know -howand trade secrets relating to the development and commercialization of the therapeutic product candidates in development by our portfolio companies, including related manufacturing processes and technologies. As of June 30, 2024, the patent portfolio of our subsidiaries includes 10 patent families of issued patents and pending patent applications in various stages of prosecution. Generally, the patents issued and patent

240

applications pending are in multiple jurisdictions including the United States, Europe, Japan, India, and China, with anticipated expiration between 2032 to 2041, without considering patent term adjustments or patent term extensions. The below table summarizes the seven patent families that have been issued to -datefor our subsidiary companies:

| Company   
 Assignee  |     | Family                                                                                        |     | Status            |     | Type                                 |     | Granted                            
 Regions                            |     | Expiration 
       Year |
| Vaximm    |     | Manufacturing (1)                                                                             
 WO 2013/091898, Method for Producing High Yield Attenuated Salmonella Strains                 |     | Owned             |     | Manufacturing